HomeCompareOBSV vs VIG

OBSV vs VIG: Dividend Comparison 2026

OBSV yields 1964.64% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OBSV wins by $8418661323.97M in total portfolio value
10 years
OBSV
OBSV
● Live price
1964.64%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8418661324.00M
Annual income
$7,652,437,982,425,691.00
Full OBSV calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — OBSV vs VIG

📍 OBSV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOBSVVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OBSV + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OBSV pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OBSV
Annual income on $10K today (after 15% tax)
$166,994.11/yr
After 10yr DRIP, annual income (after tax)
$6,504,572,285,061,837.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, OBSV beats the other by $6,504,572,285,061,685.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OBSV + VIG for your $10,000?

OBSV: 50%VIG: 50%
100% VIG50/50100% OBSV
Portfolio after 10yr
$4209330662.02M
Annual income
$3,826,218,991,212,935.00/yr
Blended yield
90.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on OBSV right now

OBSV
Analyst Ratings
9
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$6.00
+5793.9% upside vs current
Range: $6.00 — $6.00
Altman Z
-39.0
Piotroski
4/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OBSV buys
0
VIG buys
0
No recent congressional trades found for OBSV or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOBSVVIG
Forward yield1964.64%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8418661324.00M$32.4K
Annual income after 10y$7,652,437,982,425,691.00$179.15
Total dividends collected$8364201739.80M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: OBSV vs VIG ($10,000, DRIP)

YearOBSV PortfolioOBSV Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$207,164$196,463.65$11,304$163.92+$195.9KOBSV
2$4,025,415$3,803,750.33$12,759$166.33+$4.01MOBSV
3$73,382,907$69,075,712.04$14,382$168.52+$73.37MOBSV
4$1,255,382,398$1,176,862,688.09$16,192$170.52+$1255.37MOBSV
5$20,159,078,828$18,815,819,662.20$18,210$172.34+$20159.06MOBSV
6$303,950,265,341$282,380,050,994.39$20,460$173.98+$303950.24MOBSV
7$4,304,301,356,343$3,979,074,572,429.02$22,968$175.48+$4304301.33MOBSV
8$57,267,735,234,320$52,662,132,783,032.35$25,763$176.83+$57267735.21MOBSV
9$716,096,580,908,859$654,820,104,208,136.60$28,878$178.05+$716096580.88MOBSV
10$8,418,661,323,998,170$7,652,437,982,425,691.00$32,350$179.15+$8418661323.97MOBSV

OBSV vs VIG: Complete Analysis 2026

OBSVStock

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Full OBSV Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this OBSV vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OBSV vs SCHDOBSV vs JEPIOBSV vs OOBSV vs KOOBSV vs MAINOBSV vs DGROOBSV vs NOBLOBSV vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.